Verana Health and Janssen Enter Real-World Data and Data Science Collaboration


Verana Health has entered into a research collaboration with Janssen Research & Development, a unit of Johnson & Johnson, that focuses on curating real-world data and driving data science applications in ophthalmology, as well as urology. Financial terms of the agreement were not disclosed.

Last year, MedCity News broke down how Verana changed from a tele-ophthalmology start-up to a data analytics company, and closed a $100 million funding round led by GV, formerly Google Ventures.

Roots in Ophthalmology
Verana started in 2017 as a partnership with the American Academy of Ophthalmology (AAO) to analyze data from the AAO-sponsored IRIS (Intelligent Research in Sight) Registry, the largest specialty-based clinical data registry in medicine. Since then Verana has entered into similar arrangements with the American Academy of Neurology and the American Urological Association.

“Verana works with many life science companies, in and outside of ophthalmology, and will continue to work with existing and future customers to deepen the understanding of diseases, inform clinical study design, and enhance the execution of clinical trials,” said Hylton Kalvaria, SVP, commercial and strategic partnerships at Verana.

How Janssen Collaboration Will Work
The collaboration with Janssen will transform real-world data into organized, actionable datasets. It supports Verana’s mission to further enhance the utilization of real-world evidence and specialized data science to accelerate clinical research and development, with the ultimate goal of improving patient outcomes.

“Specifically in ophthalmology, Verana will use real-world data from the American Academy of Ophthalmology’s IRIS Registry to help characterize baseline patient attributes, disease progression, and treatment-based outcomes in diabetic macular edema research that is currently limited in this population,” Kalvaria said. Diabetic macular edema is a complication of diabetes that impacts 750,000 Americans.

Verana uses de-identified data from patient registries, along with software that gives physicians a view of how their practice is performing, and tools that can track factors that lead to better patient outcomes.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

4DTM Goes It Alone After Roche Pulls Out of Gene Therapy Trials (1)

4DTM Goes It Alone After Roche Pulls Out of Gene Therapy Trials

Second Sight Gets a Double-Shot Boost Thanks to PO and NIH installment 2

Second Sight Gets a Double-Shot Boost Thanks to PO and NIH installment

Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars copy

Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars

Two Steps Forward for Clearside’s SCS Suprachoroidal Platform (1)

Two Steps Forward for Clearside’s SCS Suprachoroidal Platform

Heru Closes $30 Million Series A Round

Heru Closes $30 Million Series A Round

Apellis Building on Its Platform with APL-2 for Geographic Atrophy Social

Apellis Building on Its Platform with APL-2 for Geographic Atrophy

About The Author

Steve Lenier

Steve Lenier began a career in medical literature over 30 years ago. He has worked on a variety of publications and projects, and across a number of specialties. Since 2005 most of his time has been spent covering ophthalmology, both print and online.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

PODCASTS